Novo Nordisk (NVO) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $202.98B | Exchange | NYSE |
| Sector | Healthcare | Industry | Biotechnology |
| Country | DK | CEO | Maziar Mike Doustdar |
| IPO Date | 1981-04-30 | CAGR | 11.37% |
| Employees | 68,794 | Website | www.novonordisk.com |
| Div. Yield | 3.13% | Payout Ratio | 45% |
| Buy Back Yield | 2.3% | Total Yield | 5.43% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $1487.16B | P/E | 11.37 | Forward P/E | 2.04 | PEG | -0.55 |
| P/S | 5.05 | P/B | 7.48 | P/CF | 12.45 | P/FCF | 33.96 |
| Sales | $50.93B | Sales 1Y | 5.61% | Sales 3Y | 63.63% | Sales 5Y | 153.58% |
| EPS | $4.02 | EPS 1Y | 5.01% | EPS 3Y | 75.77% | EPS 5Y | 173.67% |
| Sales QoQ | -18.94% | EPS QoQ | -56.55% | Sales QoQ Avg | 1.63% | EPS QoQ Avg | 8.45% |
| Gross Margin | 80.65% | Operating Margin | 43.13% | Profit Margin | 35.35% | ROCE | 39.93% |
| ROA | 20% | ROE | 59% | Altman Z Score | 3.93 | Piotroski Score | 6 |
| Current Ratio | 0.87 | Quick Ratio | 0.66 | Cash Ratio | 0.19 | Op. CF Ratio | 0.23 |
| Debt/Equity | 0.63 | Debt/Assets | 0.24 | Lt Debt/Equity | 0.55 | Lt Debt/Cap. | 0.36 |
| Intrst Cov. | 86.86 | Inventory Turnover | 1.24 | Asset Turnover | 0.55 | Receivables Turnover | 3.04 |
| Enterprise Value | $1487.16B | P/E Ratio | 11.37 |
| Forward P/E | 2.04 | PEG Ratio | -0.55 |
| P/S Ratio | 5.05 | P/B Ratio | 7.48 |
| P/CF Ratio | 12.45 | P/FCF Ratio | 33.96 |
| EPS | $4.02 | EPS Growth 1Y | 5.01% |
| EPS Growth 3Y | 75.77% | EPS Growth 5Y | 173.67% |
| Revenue Growth 1Y | 5.61% | Gross Margin | 0.81% |
| Operating Margin | 0.43% | Profit Margin | 0.35% |
| ROE | 0.59% | ROA | 0.2% |
| ROCE | 0.4% | Current Ratio | 0.87 |
| Quick Ratio | 0.66 | Cash Ratio | 0.19 |
| Debt/Equity | 0.63 | Interest Coverage | 86.86 |
| Altman Z Score | 3.93 | Piotroski Score | 6 |
Novo Nordisk (NVO) valuation & financials
Novo Nordisk (NVO) has a market capitalization of $202.98B and trades at a price-to-earnings ratio of 11.4. It operates in the Healthcare sector (Biotechnology).
Novo Nordisk's revenue grew +5.6% over the last year.
Novo Nordisk's next earnings report is scheduled for November 4, 2026; analysts estimate EPS of $0.80. Check the earnings calendar to see all companies reporting this week.
Novo Nordisk (NVO) — frequently asked questions
When does Novo Nordisk (NVO) report earnings next?
Novo Nordisk is expected to report earnings on November 4, 2026. Analysts estimate EPS of $0.80.
What is Novo Nordisk's market cap?
Novo Nordisk (NVO) has a market capitalization of $202.98B.
What is NVO's P/E ratio?
Novo Nordisk trades at a price-to-earnings ratio of 11.4, with trailing twelve-month EPS of $4.02.
How fast is Novo Nordisk growing?
Novo Nordisk's revenue grew +5.6% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)